These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 10600300)

  • 1. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
    Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
    Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
    Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
    Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide.
    Chambers JT; Chambers SK; Kohorn EI; Carcangiu ML; Schwartz PE
    Gynecol Oncol; 1996 Mar; 60(3):438-42. PubMed ID: 8774654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
    Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
    J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
    Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H
    Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront intraperitoneal chemotherapy for patients with epithelial ovarian cancer: long-term follow-up of a previously published trial.
    Del Prete SA; Ruppel MC; Hinchey JM; Del Prete CJ; Weinstein PL
    Conn Med; 2009; 73(10):581-3. PubMed ID: 19947055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
    Morris M; Gershenson DM; Burke TW; Kavanagh JJ; Silva EG; Wharton JT
    Obstet Gynecol; 1990 Dec; 76(6):1020-4. PubMed ID: 2234710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
    Gemignani ML; Hensley ML; Cohen R; Venkatraman E; Saigo PE; Barakat RR
    Gynecol Oncol; 2001 Jan; 80(1):16-20. PubMed ID: 11136563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
    Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.